Results: In 796 patients of the CAIRO study a high BMI was associated with better median OS (8.0, 14.9, 18.4 and 19.5 months for BMI categories A, B, C, and D, respectively; P = 0.001), and was an independent prognostic factor for OS in a multivariate analysis.
1.

Introduction
Obesity is associated with serious comorbidities, and its prevalence is increasing worldwide. 1 Increased body mass index (BMI) is a risk factor for the development of several types of cancer, including colorectal cancer. 2, 3 Furthermore, several studies have shown an association between obesity and colon cancer recurrence and/or colon cancer specific mortality. [4] [5] [6] [7] However, results are ambiguous and may differ per class of obesity and gender. For example, in a study among patients receiving adjuvant chemotherapy for colon cancer, very obese patients (BMI > 35 kg/m 2 ) had a statistically significant increase of 27% in cancer recurrence or death due to colon cancer compared to normal weight patients. 5 Also in patients with stage II or III rectal cancer, obese men were more likely to have local recurrence. 8 However, Meyerhart et al. found that in patients with stage III colon cancer, BMI was not associated with an increased risk of cancer recurrence and death. 9 The mechanisms by which obesity induces or promotes tumourigenesis vary by cancer site and may include insulin resistance, bioavailability of endogenous sex steroids, and localised inflammation. 10 In obese patients receiving chemotherapy pathophysiological modifications may affect parameters, such as volume distribution and drug clearance.
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Whether these mechanisms also influence survival in the advanced tumour stage is unknown. The role of obesity in patients with advanced colorectal cancer (ACC) has not been established. Therefore, we examined the influence of BMI on outcome in ACC patients participating in two large randomised phase III studies.
Patients and methods
Study population
For this analysis prospectively collected data were obtained from ACC patients participating in the CAIRO and CAIRO2 study. Both studies were performed by the Dutch Colorectal Cancer Group (DCCG). The CAIRO study is a randomised phase III study with 820 patients in which the sequential versus the combined use of capecitabine, irinotecan and oxaliplatin was investigated (ClinicalTrials.gov NCT00312000). 12, 13 Patients were randomised to receive either first-line treatment with capecitabine, secondline irinotecan and third-line capecitabine plus oxaliplatin (sequential treatment) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment). In the CAIRO2 study 755 patients were randomly assigned between first line treatment with capecitabine, oxaliplatin and bevacizumab with (arm B) or without (arm A) cetuximab (ClinicalTrials.gov NCT00208546). 14, 15 In both studies, assessment of tumour response was scheduled every 3 cycles (9 weeks) according to Response Evaluation Criteria in Solid Tumours (RECIST). 16 Details of eligibility criteria and results have been reported elsewhere. ) were analysed separately for toxicity.
Statistical evaluation
Differences between patient characteristics among the four BMI categories were calculated using v 2 test for categorical variables and the Kruskal-Wallis test for numerical variables. We also used v 2 and Kruskal-Wallis test to analyse differences in toxicity and median number of cycles, respectively. OS and PFS curves were estimated using the Kaplan-Meier method and compared with the log-rank test. In order to determine whether BMI was an independent prognostic factor and to adjust for the impact of potential confounders, a Cox proportional hazard model was used including treatment arm, gender, WHO performance status, serum LDH level, leucocytes, and number of metastatic sites. Survivors were censored at the date of last follow up. SAS version 8.2 was used for statistical analysis. All tests were two-sided, and P values of less than 0.05 were considered as statistically significant.
Results
BMI baseline characteristics
The distribution over the four different BMI categories was comparable between the two study populations and was representative for the general Dutch population. 18 The study population of the CAIRO2 study was comparable to the CAIRO study population, except for age and performance status, since patients with a performance status of 2 were excluded in the CAIRO2 study. Seven out of the 803 eligible patients in the CAIRO study were excluded because they never started with first line treatment. Of the 796 patients who were eligible for analysis, 14 (2%) patients were assigned to BMI category A, 380 (48%) to category B, 306 (38%) to category C and 96 (12%) to category D. Overweight patients were slightly older compared to the normal weight patients (P = 0.006). Baseline characteristics of the patients were comparable between the different BMI groups for gender, performance status (0-1 versus 2), LDH at randomisation (normal versus abnormal), leucocytes (<10 ver-sus P10 · 10 9 /l), prior adjuvant chemotherapy (yes versus no) and number of metastatic sites (Table 1 ).
In the CAIRO2 study, 730 out of the 736 eligible patients were included in this analysis; 6 patients were excluded because they never started with first line treatment and/or no data on baseline height and weight were available. Twelve (2%) patients were underweight, 359 (49%) had a normal weight, 274 (37%) were overweight and 85 (12%) patients were obese. Patient characteristics of the CAIRO2 study population are shown in Table 2 . Although the numbers in category A and D are low, patients with low BMI were of younger age, more likely to be female, and more often had a worse performance status. Patients with high BMI more often had received adjuvant chemotherapy. Other baseline characteristics were well balanced between the different BMI categories.
BMI and outcome in CAIRO study
An increasing BMI was significantly associated with a better median OS (8.0, 14.9, 18.4 and 19.5 months for BMI category A, B, C and D, respectively; P = 0.001) ( Table 3 , Fig. 1 ). At the time of analysis, 719 of the 796 eligible patients had died, 367 in the sequential arm and 352 in the combination arm, the remainder was censored at the last date of follow-up. There was no difference in PFS between four BMI categories (4.4, 6.2, 7.2 and 7.0 months for category A, B, C, and D, respectively; P = 0.153).
The median number of treatment cycles increased with increasing BMI, although this was not significantly different (P = 0.392). The percentage of patients that received all three cytotoxic drugs, second line treatment, and third line treatment was comparable between the four different groups. The incidence of first line grade 3-4 toxicity did not differ between the four BMI categories (P = 0.363). Furthermore, patients who received a capping dose experienced an equivalent amount of grades 3-4 toxicity compared to patients who did not receive a capping dose (sequential arm 25% versus 30%, P = 0.708; combination arm 60% versus 66%, P = 0.793).
A multivariate analysis including treatment arm, gender, serum LDH, leucocytes, number of metastatic sites, and performance status showed that BMI was an independent prognostic factor for OS with a hazard ratio (HR) for death of 1.644 (95% CI 0.893-3.025; P = 0.110), 0.807 (95% CI 0.675-0.963; P = 0.018) and 0.728 (95% CI 0.551-0.961; P = 0.025) for BMI category A, C and D, respectively, compared to category B (Table 5 ) HR for death was 0.42 (95% CI 0.24-0.75; P = 0.002) for obese patients compared to underweight patients in a test across categories.
3.3.
BMI and outcome in CAIRO2 study
In the CAIRO2 study population, a total of 518 patients had died, 249 in arm A and 269 in arm B. The remainder was 
Fig . 2) . The median PFS, median number of cycles and incidence of grades 3-4 toxicity were comparable among the four BMI categories. Normal weight patients less often received second line treatment compared with the other BMI categories. In a multivariate analysis including treatment arm, gender, serum LDH, leucocytes, number of metastatic sites and performance status, BMI was not associated with OS. HR for death was 1.092 (95% CI 0.575-2.073; P = 0.788), 0.996 (95% CI 0.819-1.211; P = 0.965) and 0.992 (95% CI 0.740-1.331; P = 0.959) for BMI category A, C and D, respectively, compared to category B (Table 6 ).
Discussion
We observed that BMI was an independent prognostic factor for OS in the study cohort of ACC patients treated with chemotherapy. However, this finding was not confirmed in a second cohort of ACC patients treated with chemotherapy plus targeted therapy with comparable baseline characteristics who participated in a subsequent study.
In obese patients, hyperinsulinemia may increase the risk of colorectal cancer by increased levels of unbound insulinlike growth factor 1, which increases proliferation and metastasis of cancer cells. 19, 20 Furthermore, adipose tissue-derived hormones may play a role in tumourgenesis. 10 Though obesity has also shown to contribute to cancerrelated mortality, 7 a high BMI has been associated with a favourable prognosis in various tumour types, including cervical cancer, 21 head and neck cancer, oesophageal cancer 22 and clear cell renal cell carcinoma. 23 However, these studies concerned all tumour stages, and BMI was associated with cofactors, such as age and tumour grading. It is assumed that underweight cancer patients have a worse survival because cachexia may be a reflection of advanced stage and an aggressive type of tumour. However, in the CAIRO study, not only a decreased OS was found in underweight patients compared to normal weight patients, but also a better OS was found in overweight and obese patients. Maybe obese patients have better nutritional resources to withstand the devastating effect of cancer itself. Of note, no difference in known prognostic factors was observed between the different BMI categories. Several other hypotheses have been presented. In obese patients pathophysiological modifications may affect parameters, such as volume distribution and drug clearance. Therefore the efficacy and toxicity of chemotherapy may be altered in obese patients. For example, the more lipophilic an agent, the more likely the volume of distribution will be affected. 11 Miya et al. reported that BMI was an independent prognostic predictor of peak plasma concentrations of irinotecan. 24 However, in our study the incidence of toxicities was comparable between the obese and normal weight patients, and between the patients who had dose capping and those who were dosed according to their actual body weight. This does not support that a relative overdosing of obese patients of lipid insoluble drugs such as irinotecan might explain the difference in median OS.
BMI was not associated with OS in a multivariate analysis in the study cohort of patients treated with chemotherapy and targeted therapy, although a trend for better OS was observed in higher BMI categories. Patient characteristics were comparable in the two study cohorts. However, in the second cohort, age and performance status were significantly different among the four BMI categories, with patients in the higher BMI categories having a better performance status. The differences in age are of a magnitude that is unlikely to be clinically relevant. Possible potential confounders of both studies have to be taken into account. Data on smoking habits were not collected. The influence of cardiovascular disease as potential confounder is probably limited, since patients with significant cardiovascular disease were excluded in both studies. We did analyse the use of statins in the CAIRO and CAIRO2 study, since statins may have a beneficial effect on colorectal cancer prognosis. 25 In both studies, no difference in statin use was observed among the four BMI categories and in univariate and multivariate analysis the use of statins was not correlated with OS (data not shown).
A major difference between the two study cohorts is that targeted therapy, including bevacizumab, was used in the CAIRO2 study but not in the CAIRO study, due to the fact that bevacizumab was not yet approved for use at that time. Guiu et al. showed that ACC patients with a high BMI who received first line bevacizumab-based therapy had a shorter time to progression compared to normal weight patients. Furthermore, a high visceral fat area was an independent negative predictor for survival. This association of body fatness with outcomes was not observed in patients treated with chemotherapy without bevacizumab. The authors explained these results by a larger volume of distribution of bevacizumab in obese patients or increased levels of vascular endothelial growth factor produced by visceral fat, which may be associated with resistance to bevacizumab. 26 This hypothesis is supported by our results which show a larger survival benefit for the addition of targeted therapy to chemotherapy in patients with BMI categories A and B versus patients with BMI categories C and D. However, this concerns a cross-study comparison (CAIRO versus CAIRO2), and, therefore, this should be interpreted with caution.
In conclusion, we found that BMI is an independent prognostic factor for OS in ACC patients receiving chemotherapy. However, this was not confirmed in a second cohort of ACC patients with comparable patient characteristics receiving chemotherapy plus targeted therapy, although a non-significant trend towards improved OS with higher BMI was observed. These results may be explained by a decreased efficacy of bevacizumab in obese patients. Further studies should confirm this finding.
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